List view / Grid view
21 May 2014 | By Novartis
Novartis announced new data from the QUANTIFY study, which demonstrated the non-inferiority of Ultibro® Breezhaler® (indacaterol/glycopyrronium) 110/50 mcg compared to tiotropium 18 mcg plus formoterol 12 mcg...
20 May 2014 | By Novartis
Novartis announced the signing of a licensing and commercialization agreement with Ophthotech Corporation for the exclusive rights to market Fovista® outside the United States...
16 May 2014 | By Novartis
Novartis announced that the US Food and Drug Administration has issued a Complete Response Letter regarding the Biologics License Application for RLX030...
15 May 2014 | By Novartis
Novartis Pharmaceuticals Corporation has settled its litigation with the United States subsidiary of Sun Pharmaceutical Industries Ltd. relating to Novartis patents covering the use of certain polymorphic forms of Gleevec®...
6 May 2014 | By Novartis
Novartis presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR in patients with acromegaly for whom current standard of care provides inadequate disease control...
25 April 2014 | By Novartis
Novartis announced top-line results from the Phase IV INSTEAD switch study in patients with chronic obstructive pulmonary disease, which met its primary objective...
22 April 2014 | By Novartis
Novartis announced that it has reached a definitive agreement with GlaxoSmithKline plc to exchange certain assets, building global leadership in key segments and focusing the company's portfolio...
22 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announces a major 3-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses...
9 April 2014 | By Novartis
Novartis announced the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014...
7 April 2014 | By Novartis
Novartis announced that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign...
4 April 2014 | By Novartis
Novartis announced that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research...
31 March 2014 | By Novartis
Novartis announced that the Data Monitoring Committee unanimously recommended early closure of the PARADIGM-HF study...
21 March 2014 | By Novartis
Novartis announced that the Joint Committee on Vaccination and Immunisation in the UK has recommended the inclusion of Bexsero® (Meningococcal Group B Vaccine...
20 March 2014 | By Novartis
Novartis has announced the launch of the Lucentis® (ranibizumab) pre-filled syringe in Germany, with other markets to follow throughout 2014...
13 March 2014 | By Novartis
Novartis has announced that Australia has joined the growing number of countries where following licensure, Bexsero® has received a clinical recommendation...
